Receipt date: 10/30/2017
`
`15/789,862 - GAU: 1674
`
`PTOISBI'DBa (03-15)
`Doc code' IDS
`Approved for use through 071312016. OMB 0651-0031
`.
`.
`.
`_
`'.
`.
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Doc description. Information Disclosure Statement (IDS) Filed
`Under the Paperwork Reduction Act of 1995. no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`| 5789862
`
`
`I N
`
`i'A
`
`Application Number
`Filing Date
`
`First Named Inventor
`
`
`
`
`IN FORMATION DISCLOSU RE
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`Art Unit
`
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`I AVN-OOQDVCNT
`
`
`
`
`
`
`
`
`U.S.PATENTS
`-
`
`
`Examiner Cite
`Initial*
`NO
`
`Patent Number
`
`Kind
`Code1 Issue Date
`
`Name of Patentee or Applicant
`Of cited Document
`
`Pages,ColumnS,LineS where
`Relevant Passages or Relevant
`Figures Appear
`
`
`
`If you wish to add additional US. Patent citation information please click the Add button.
`Add
`U.S.PATENT APPLICATION PUBLICATIONS -
`
`
`Examiner Cite No Publication
`Initial*
`Number
`
`Publication
`Kind
`Code1 Date
`
`Name of Patentee or Applicant
`Of cited Document
`
`Pages,ColumnS,LineS where
`Relevant Passages or Relevant
`Figures Appear
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`If you wish to add additional U.S. Published Application citation information please click the Add button. Add
`FOREIGN PATENT DOCUMENTS
`-
`
`
`
`Pages,Columns,LineS
`
`Name of Patentee or
`
`where Relevant
`Kind
`Publication
`
`Examiner Cite Foreign Document
`Applicant Of cited
`T5
`|nitia|*
`No
`Number3
`
`Code4 Date
`Passages or Relevant
`
`
`Document
`
`
`Figures Appear
`
`
`
`If you wish to add additional Foreign Patent Document citation information please click the Add button
`NON-PATENT LITERATURE DOCUMENTS -
`
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item
`T5
`(book, magazine, journal, serial, symposium, catalog, etc), date, pageS(S), volume-issue number(s),
`publisher, city and/or country where published.
`
`
`EFSWeb2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/JPM/
`
`

`

`
`Receiptdajze; 10/10/2013
`15/789j52 —GAU: 1574
`
`Application Number
`15789862
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`
`
`
`
`
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art Unit
`|NIA
`
`
`
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`|AVN-009DVCN7
`
`S Transmittal, application as—filed, and Preliminary Amendment for Application No. 131271,080, 115 pages, dated
`october 11, 2011 (Exhibit Number 2111 filed in interferences 106008, 106013, 106007 on November 18, 2014)
`
`S Updated Filing Receipt for Application No. 131550210, 3 pages, dated December 11, 2012 (Exhibit Number 2044
`"ed in interferences 106008, 106013, 106007 on November 18, 2014)
`
`SPTO "2014 Procedure for Subject Matter Eligibility Analysis of Claims Reciting or Involving. . .Natural Products" ("the
`arch Guidance“), 19 pages, (Exhibit Number 2118 filed in interferences 106,007 and 106,008 on February 17, 2015.
`
`SPTO Written Description Training Materials, Revised March 25, 2008, Example 12, 6 pages, (Exhibit Number 1068
`"ed in interferences 106008, 106007 on December 23, 2014)
`
`WA Clean Copy of Claims and Sequence, as filed in Interference No. 106,007 on August 1, 2014 (Paper 12), 8
`ages, (Exhibit Number 2126 filed in interferences 106,007 and 106,008 on February 17, 2015.
`
`WA Clean Copy of Claims and Sequence, as filed in Interference No. 106,007 on August 7, 2014 (Paper 12), 8
`ages, (Exhibit Number 2127 filed in interferences 106,007 and 106,008 on February 17, 2015.
`
`WA Motion 1 (For Judgment Under 35 § 112(a)) from Int. No. 106,007 (PN210), 40 Pages, Exhibit Number 1005 filed
`n Interference 106,013 on February 17, 2015.
`
`WA Motion 1 (For Judgment Under 35 § 112(a)) from Int. No. 106,008 (Doc 213), Pages 38, Exhibit Number 1004
`"ed in Interference 106,013 on February 17, 2015.
`
`WA submission of teleconference transcript , 28 pages, dated December 12, 2014 (Exhibit Number 2114 filed in
`nterferences 106008 and 106007 on December 12, 2014)
`
`alorization Memorandum published by the Dutch Federation of University Medical Centers in March 2009, (University
`f Western Australia Exhibit 2140, filed April 3, 2015 in lnterferences 106007, 106008, and 106013, pages 1—33).
`
`AN DEUTEKOM et al., "Antisense-induced exon skipping restores dystrophin expression in DMD patient derived
`uscle cells," HUMAN MOLECULAR GENETICS Vol. 10, No. 15: 1547—1554 (2001) (Exhibit Number 1084 filed in
`nterferences 106008, 106007 on December 23,2014)
`
`EFS Web 2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/JPM/
`
`

`

`
`Receiptdajze; 10/10/2013
`15/789j52 —GAU: 1574
`
`Application Number
`15789862
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art Unit
`|NIA
`
`
`
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`|AVN-009DVCN7
`
`—l—l
`
`—l
`
`(A)N
`
`4:.
`
`—l—l"NlU'i
`
`AN DEUTEKOM et at, "Local Dystrophin Restoration with Antisense Oligonucleotide PR0051," N. Engl. J. Med., Vol.
`:57, No. 26, pp. 2677—2686 (December, 2007), Exhibit Number 1213 filed in Interferences 106,007 and 106,008 on
`ebruary 17, 2015.
`
`AN DEUTEKOM, Judith C. T. et al., "Advances in Duchenne Muscular Dystrophy Gene Therapy," Nature Reviews
`enetics, Vol. 4(10):774—783 (2003)
`
`an Ommen 2002 PCT (WO 02/24906 AI), 43 pages,(Exhibit Number 1071 filed in interferences 106008, 106007 on
`I ecember 23, 2014)
`
`an Putten M, et al., "The Effects of Low Levels of Dystrophin on Mouse Muscle Function and Pathology. PLoS ONE
`'012;7:e31937, 13 pages
`
`an Vliet, Laura et al., "Assessment of the Feasibility of Exon 45—55 Multiexon Skipping for Duchenne Muscular
`Iystrophy", BMC Medical Genetics, Vol.9(1):105 (2008)
`
`ERMA, Sandeep et al., "Modified Oligonucleotides: Synthesis and Strategy for Users," Annu. Rev. Biochem, Vol.
`.7z99—134 (1998) (Exhibit Number 1040 filed in interferences 106008, 106007 on November 18, 2014)
`
`ikase Corp. v. Am. Nat'l. Can 00., No. 93—7651, 1996 WL 377054 (N.D. |||. July 1, 1996), 3 pages (Exhibit Number
`' 152 filed in interference 106013 on October 29, 2015)
`
`OIT, Thomas et al., "Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND
`I): an exploratory, randomised, placebo—controlled phase 2 study," Lancet Neuro|., Vol. 13:987-996 (2014) (Exhibit
`umber 2037 filed in interferences 106008, 106013, 106007 on November 18, 2014)
`
`
`
`
`
`
`
`O
`
`OLLOCH, Vladimir et al., "Inhibition of Pre—mRNA Splicing by Antisense RNA in Vitro: Effect of RNA Containing
`equences Complementary to Exons," Biochemical and Biophysical Research Communications, Vol. 179
`3):1593—1599 (1991)
`
`ahlestedt et al., "Potent and nontoxic antisense oligonucleotides containing locked nucleic acids," PNAS, Vol. 97,
`o. 10, pp. 5633—5638 (May, 2000), Exhibit Number 1201 filed in Interferences 106,007 and 106,008 on February 17,
`
`ang et al., "In Vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for
`I uchenne muscular dystrophy," J. Gene Medicine, Vol. 12, pp. 354-364 (March, 2010), Exhibit Number 1115 filed in
`nterferences 106,007 and 106,008 on February 17, 2015.
`
`|\J|\J
`
`—|
`
`|\JN
`
`EFS Web 2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/JPM/
`
`

`

`
`Receipt. date; Ill/MUM
`15/7&9,_8_62 — GAU: 1574
`
`15789862
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Ar, Unit
`|NIA
`
` Application Number
`
`
`
`Examiner Name
`Not Yet Assigned
`
`Attorney Docket Number |AVN-009DVCNT
`
`|\J00
`
`|\J4:.
`
`|\JUt
`
`00|\J|\J|\J|\JO(.0CO"-I0')
`
`00 _.
`
`00N
`
`0000
`
`ANG, Chen-Yen et al., "pH—sensitive immunoliposomes mediate target—ceII-specific delivery and controlled
`xpression of a foreign gene in mouse," Proc. Natl. Acad. Sci. USA, Vol. 847851-7855 (1987)
`
`ATAKABE, Akiya et al., "The role of exon sequences in splice site selection," Genes & Development, Vol. 7:407-418
`1993)
`
`atanabe et al., "Plasma Protein Binding of an Antisense Oligonucleotide Targeting Human ICAM—1 (ISIS 2302),"
`oligonucleotides, Vol. 16, pp. 169— 180 (2006), Exhibit Number 1197 filed in Interferences 106,007 and 106,008 on
`ebruary 17, 2015.
`
`HO Drug Information, International Nonproprietary Names for Pharmaceutical Substances (INN), Proposed INN: List
`15, "CASIMERSEN," vol. 30(2): 3 pages (2016)
`
`H0 Drug Information, International Nonproprietary Names for Pharmaceutical Substances (INN), Proposed INN: List
`15, "Golodirsen," vol. 30(2): 3 pages (2016)
`
`IJNAENDTS, L.C.D. et al., "Prognostic importance of DNA flow cytometric variables in rhabdomyosarcomas," J. Clin.
`'athol., Vol. 46:948—952 (1993) (Exhibit Number 1041 filed in interferences 106008, 106007 on November 18, 2014)
`
`ilton et al. (2007) "Antisense Oligonucleotide—induced Exon Skipping Across the Human Dystrophin Gene
`ranscript," Molecular Therapy 15(7):1288—1296, 10 pages, (Exhibit Number 2121 filed in interferences 106,007 and
`06,008 on February 17, 2015
`
`ILTON, Stephen D. et al., "Antisense oligonucleotides in the treatment of Duchenne muscular dystrophy: where are
`e now?" Neuromuscular Disorders, Vol. 15:399-402 (2005)
`
`
`
`ILTON, Stephen D. et al., "Specific removal of the nonsense mutation from the mdx dystrophin mRNA using
`: ntisense oligonucleotides," Neuromuscular Disorders, Vol. 9:330—338 (1999)
`
`0 200224906 A1 of AZL, (University of Western Australia Exhibit 2134, filed April 3, 2015 in Interferences 106007,
`06008, and 106013, pages 1-43.)
`
`O 2004/083432 (the published AZL PCT Application, "Van Ommen"), Pages 71, Exhibit Number 1003 filed in
`nterference 106,013 on February 17, 2015.
`
`EFSWeb2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/JPM/
`
`
`
`

`

`
`Receipt. date; Ill/MUM
`15/7&9,_8_62 — GAU: 1574
`
`15789862
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art Unit
`|NIA
`
` Application Number
`
`
`
`Examiner Name
`Not Yet Assigned
`
`Attorney Docket Number |AVN-009DVCN7
`
`004:.
`
`000'1
`
`000')
`
`4:-000000O(.003"-l
`
`4:. _.
`
`4:.N
`
`4:.00
`
`4:.4:.
`
`0 20137112053 A1, (University of Western Australia Exhibit 2130,
`06008, and 106013, pages 1—177).
`
`filed April 3, 2015 in Interferences 106007,
`
`OLFF, Jon A. et al., "Direct Gene Transfer into Mouse Muscle in Vivo," Science, Vol. 247:1465-1468 (1990)
`
`ONG, Marisa L. et al., "Real-time PCR for mRNA quantitation," BioTechniques, Vol. 39:75—85 (2005) (Exhibit
`umber 1066 filed in interferences 106008, 106007 on November 18, 2014)
`
`ood, "Toward an Oligonucleotide Therapy for Duchenne Muscular Dystrophy: A Complex Development Challenge,"
`. cience Translational Medicine, Vol. 2, No. 25, pp. 1—6 (March, 2010), Exhibit Number 1116 filed in interferences
`06,007 and 106,008 on February 17, 2015,D0c 335.
`
`ritten Opinion for Application No. PCT/AU2010/001520, 6 pages, dated January 21, 2011
`
`
`
`U, B. et al., "Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by
`ystemically delivered morpholino," Gene Therapy, Vol. 17:132-140 (2010)
`
`U, Bo et al., "Effective rescue of dystrophin improves cardiac function in dystrophin—deficient mice by a modified
`orpholino oligomer," PNAS, Vol. 105(39):14814-14819 (2008)
`
`U, Bo et al., "Targeted Skipping of Human Dystrophin Exons in Transgenic Mouse Model Systemically for Antisense
`I rug Development," PLoS One, Vol. 6(5):e19906, 11 pages (2011)
`
`U, George Y. et al., "Receptor-mediated Gene Delivery and Expression in Vivo," The Journal of Biological
`hemistry, Vol. 263(29):14621-14624 (1988)
`
`U, George Y. et al., "Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System," The
`ournal of Biological Chemistry, Vol. 262(10):4429—4432 (1987)
`
`yatt et al. "Site—specific cross—linking of mammalian U5 snRNP to the 5' splice site before the first step of pre-mRNA
`plicing," Genes & Development, Vol. 6, pp. 2542-2553 (1992), Exhibit Number 1198 filed in Interferences 106,007
`: nd 106,008 on February 17, 2015.
`
`EFSWeb2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/JPM/
`
`
`
`

`

`
`Receipt. date; Ill/MUM
`15/7&9,_8_62 — GAU: 1574
`
`15789862
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art Unit
`|NIA
`
` Application Number
`
`Examiner Name
`Not Yet Assigned
`
`Attorney Docket Number |AVN-009DVCN7
`
`
`
`
`
`in et al., "A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in
`ystrophin—deficient mdx mice," Human Mol. Gen., Vol. 18, No. 22, pp. 4405-4414(2009), Exhibit Number 1200 filed in
`nterferences 106,007 and 106,008 on February 17, 2015.
`
`in et al., "Cell Penetrating peptide—conjugated antisense oligonucleotides restore systemic muscle and cardiac
`ystrophin expression and function," Human Mol. Gen., Vol. 17, No. 24, pp. 3909-3918 (2008), Exhibit Number 1199
`"ed in Interferences 106,007 and 106,008 on February 17, 2015.
`
`in et al., "Functional Rescue of Dystrophin—deficient mdx Mice by a ChimericPeptide-PMO," Mol. Therapy, Vol. 18,
`o. 10, pp. 1822—1829 (October, 2010), Exhibit Number 1117 filed in interferences 106,007 and 106,008 on February
`7, 2015.
`
`
`
`okota et al., "Efficacy of Systematic Morpholino Exon—Skipping in Duchenne Dystrophy Dogs," American Neurological
`. ssoc., Vol. 65, No. 6, pp. 667—676 (June, 2009), Exhibit Number 1214 filed in Interferences 106,007 and 106,008 on
`ebruary 17, 2015.
`
`'oltek Corp. v. US, 95 Fed. CI. 681 (2011), 23 pages, (Academisch Ziekenhuis Leiden Exhibit 1236, filed May 5,
`'015 in Interference 106007 and 106008).
`
`If you wish to add additional non-patent literature document citation information please click the Add button Add
`EXAMINER SIGNATURE
`
`Examiner Signature I /Jennifer Pitrak McDonald]
`
`Date Considered
`
`I
`
`12 /12/2017
`
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a
`citation if not in conformance and not considered.
`Include copy of this form with next communication to applicant.
`
`1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO
`Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
`4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if
`English language translation is attached.
`
`EFSWeb2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/JPM/
`
`

`

`
`Receipt. date; 10/10/2013
`15/7&9,_8_62 — GAU: 1574
`
`15789862
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art Unit
`|NIA
`
` Application Number
`
`Examiner Name
`Not Yet Assigned
`
`Attorney Docket Number |AVN-009DVCN7
`
`
`
`
`
`Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):
`
`CERTIFICATION STATEMENT
`
`That each item of information contained in the information disclosure statement was first cited in any communication
`from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
`information disclosure statement. See 37 CFR 1.97(e)(1).
`
`OR
`
`That no item of information contained in the information disclosure statement was cited in a communication from a
`
`foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
`after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
`any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
`statement. See 37 CFR 1.97(e)(2).
`
`El
`
`See attached certification statement.
`
`The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
`
`A certification statement is not submitted herewith.
`
`SIGNATURE
`
`A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the
`form of the signature.
`
`This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the
`public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR
`1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed
`application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you
`require to complete this form andlor suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S.
`Patent and Trademark Office, U.S. Department of Commerce, PO. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND
`FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria,
`VA 22313-1450.
`
`EFSWeb2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/JPM/
`
`
` NamelPrint
`Signature
`2017—10—30
`
`
`
`

`

`Receipt date: 10/30/2017
`
`15/789,862 - GAU: 1674
`
`Privacy Act Statement
`
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the
`attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised
`that:
`(1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited
`is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to
`process and/or examine your submission related to a patent application or patent.
`If you do not furnish the requested
`information, the U.S. Patent and Trademark Office may not be able to process andr'or examine your submission, which may
`result in termination of proceedings or abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1.
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act
`(5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the
`Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record 5.
`
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a
`court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement
`negotiations.
`
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
`request involving an individual, to whom the record pertains, when the individual has requested assistance from the
`Member with respect to the subject matter of the record.
`
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for
`the information in order to perform a contract. Recipients of information shall be required to comply with the
`requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
`
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
`may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
`to the Patent Cooperation Treaty.
`
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of
`National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
`
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or
`his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to
`recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and
`2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this
`purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make
`determinations about individuals.
`
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of
`the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record
`may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in
`an application which became abandoned or in which the proceedings were terminated and which application is
`referenced by either a published application, an application open to public inspections or an issued patent.
`
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law
`enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.
`
`
`
`
`
`
`
`EFS Web 2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/JPM/
`
`